PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF

摘要

PURPOSE: A pharmaceutical composition is provided to reduce electrostatic characteristics and adsorption with safety and to improve elution rate and bioavailability. CONSTITUTION: A pharmaceutical composition contains 20-1000 mg of 4-methyl-N-[3-(4-methylimidazole-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyrazine-2-yl-pyrimidine-2-ylamino)-benzamide hydrochloride as an active ingredient and a pharmaceutically acceptable excipient. The pharmaceutical composition is manufactured in the form of a granule, a powder, a tablet, a capsule, or a suspension. A method for manufacturing the pharmaceutical composition comprises the steps of wet/dry-granulating the active ingredient using a solvent or aqueous/oil cosolvent of a surfactant and/or an organic solvent as a solubilizing agent. [Reference numerals] (AA) Dissolution rate (%); (BB) Example 2; (CC) Example 3; (DD) Example 4; (EE) Comparative example 1; (FF) Comparative example 2; (GG) Comparative example 3; (HH) Comparative example 4